* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Parainfluenza Viruses
Viral phylodynamics wikipedia , lookup
2015–16 Zika virus epidemic wikipedia , lookup
Transmission (medicine) wikipedia , lookup
Vectors in gene therapy wikipedia , lookup
Infection control wikipedia , lookup
Transmission and infection of H5N1 wikipedia , lookup
Eradication of infectious diseases wikipedia , lookup
Herpes simplex research wikipedia , lookup
Marburg virus disease wikipedia , lookup
Influenza A virus wikipedia , lookup
Canine parvovirus wikipedia , lookup
CORONAVIRIDAE Introduction • Coronaviruses are named for the solar corona–like appearance (the surface projections) of their virions when viewed with an electron microscope. • Coronaviruses are the second most prevalent cause of the common cold (rhinoviruses are the first). • Coronaviruses infect humans, animals, and birds. 2 Peplomer: glycoprotein spike on a viral capsid or viral envelope 3 Classification • Coronaviridae has two genera: • Torovirus and Coronavirus • Torovirus: • The toroviruses are widespread in ungulates and appear to be associated with diarrheas • Coronavirus: • The Coronaviridae family has been divided up into three groups, originally on the basis of serological cross-reactivity, but more recently on the basis of genomic sequence homology 4 Classification • Coronaviruses of domestic animals and rodents are included in two groups • There is a third distinct antigenic group which contains the avian infectious bronchitis virus of chickens • The novel coronavirus recovered in 2003 from patients with severe acute respiratory syndrome (SARS) appears to represent a new (fourth) group of viruses. 5 6 Characteristics • Coronaviruses are pleomorphic (Virions are spherical to pleomorphic) • Diameter 60-220 nm • Enveloped, with spikes giving the virions the appearance of a crown • (+) single-stranded RNA genome • Contain two major envelope proteins: matrix and spike proteins • Internal ribonucleoprotein (RNP) is helical 7 Replication • Entry into host cell cytoplasm, probably by viropexis • Replication and particle assembly in cytoplasm • Protein synthesis occurs in two phases on infection, the genome is translated to produce a polyprotein that is cleaved to produce an RNA-dependent RNA polymerase • The polymerase generates a negative-sense template RNA • RNA is used to replicate new genomes and produce five to seven individual mRNAs for the individual viral proteins • Progeny virions are released by budding from membranes of rER and transported through vesicles 8 9 Pathogenesis • It is thought that 2–10 per cent of common colds are caused by coronaviruses, typified by OC43 and 229E. • Infection can precipitate wheezing in asthmatics and aggravate chronic bronchitis in adults. • In a typical case there is an incubation period of 3 days, followed by an unpleasant nasal discharge and malaise, lasting about a week. • Patients excrete virus during this period. • There is a little or no fever, and coughs and sore throat are not common. 10 Pathogenesis • Replication is confined to the cells of the epithelium in the upper respiratory tract. • Infection remains localized to the upper respiratory tract because the optimum temperature for viral growth is 33°C to 35°C. • Less is known about the toroviruses. • They are often visualized in diarrhoea samples and may cause gastroenteritis. 11 Epidemiology • Coronavirus colds occur in the colder months of winter and early spring with sizable outbreaks every 2-4 years. • Most people have been infected in their lives • Reinfections are quite common either because of the poor immune response, or as a result of antigenic mutations, or both. • The virus is most likely spread by aerosols and in large droplets (e.g., sneezes). 12 Laboratory Diagnosis • The trivial nature of the infection does not call for routine diagnostic tests. • For epidemiological purposes, paired acute and convalescent sera can be tested by hemagglutination inhibition for a rising titer of specific antibody. • Virus isolation requires organ cultures of human embryo trachea or nasal epithelium • 13 Treatment & Prevention • Specific treatment • There is no specific treatment for coronaviruses. • Treatment is symptomatic and supportive. • Prevention • General hygiene and disinfection can prevent person-to person spread. • No vaccine is available. 14 Severe Acute Respiratory Syndrome (SARS CoV) • The first cases of a new syndrome emerged in November 2002 in the Guangdong Province of China. • By April 2003 the virus had spread worldwide • Unexpectedly, the virus was identified as a coronavirus (CoV), which emerged suddenly from a mammalian reservoir in China to infect humans, probably the civet cat, which is used for exotic foods, or a rat upon which the civet preys. 15 Global spread of SARS. Emergence of SARS from a civet cat or rat. 16 SARS CoV - Epidemiology • Between November 2002 and July 2003, 8096 probable SARS cases were reported to the World Health Organization. • The total number of deaths rose to 774, with a case mortality rate of 9.6%. Since then, three laboratory-associated outbreaks occurred, with a total of 11 cases. • Since then SARS has not been circulating. • SARS-CoV entered the human population from an animal source – several animals have been found to have very closely related viruses. • Spread of the virus was via respiratory droplets and, therefore, contact with surfaces was important. • Since it was excreted via the gastrointestinal tract, faecal–oral transfer was a possibility. • The incubation period was 4–6 (range 1–14) days and patients were only infectious during the symptomatic period and most infectious during the second week of illness. 17 SARS CoV - Pathogenesis • Determining the pathogenesis of SARS was difficult, based on autopsy findings confused by the effects of treatment, e.g. ventilation and medication. • The virus replicates in the lower respiratory tract, followed by an innate and a specific immune response, and both viral factors and immune response (e.g. cytokine dysregulation) play a role in the pathogenesis. • The first stage of the disease is associated with diffuse alveolar damage, macrophage and T-cell infiltration, and type 2 pneumocyte proliferation. • The pulmonary infiltrate appears patchy on the chest X-ray. • In the second stage, organisation occurs. • The infection is not limited to the pulmonary system. • The virus replicates in enterocytes, resulting in diarrhea, and is shed in the stool, as well as urine, and possibly other body fluids. 18 SARS CoV - Clinical picture • The first phase of the disease consists of fever > 38°C with rigors, myalgia, sore throat and gastrointestinal symptoms, with cough and often shortness of breath beginning after about 3–7 days of symptoms. • Hypoxia may develop and 10–20% require ventilation. • A relative lymphopenia and neutropenia may occur. • Some patients showed a biphasic course, with apparent recovery followed by worsening of the clinical condition. • Mortality was highest in the elderly and lowest in the younger population, and co-existing illness worsened morbidity and mortality. 19 SARS CoV – Laboratory Diagnosis • Specimen: • Nasopharyngeal swab or aspirate, throat swab or stool specimens may be collected for laboratory diagnosis. • Serum is used for antibody detection. • Reverse transcription PCR—(RT-PCR) • RT-PCR has been used for early diagnosis. • Virus culture: • Virus in clinical specimens can be cultured on Vero cell lines. • Serology: • Demonstration of rise in titer of antibodies by “ELISA or indirect immunofluorescent test in paired serum samples are useful later. • However, for early diagnosis PCR is preferred 20 SARS CoV - Treatment • Supportive treatment, such as ventilation, was the centerpiece of the management of a SARS patient. • Specific treatments, such as steroids, remain controversial regarding their effect, whether adverse or beneficial, on SARS patients. • Ribavirin was used, as it is a broad-spectrum guanosine analogue, and appeared to have some benefit, • Other agents that have an effect on the inflammatory response, such as chloroquine and interferon, and agents that interfere with coronavirus protease activity, such as the lopinavir/ritonavir combination. 21 SARS CoV - Prevention • Isolation of infected patients and quarantine of exposed people, along with disinfection and infection control precautions, were the key to prevention of spread. • A vaccine has been investigated, but may be merely an academic measure, relevant to future vaccine research, since the epidemic is over and SARS is no longer circulating. 22 PARAMYXOVIRIDAE Introduction • Family Paramyxoviridae causes a variety of diseases, predominantly involving the respiratory tract, in humans, birds, and other animals. • In humans, they include: • • • • measles, respiratory infections caused by respiratory syncytial virus (RSV) and parainfluenza viruses, and the more innocuous salivary gland infection of mumps. 24 Characteristics • • • • • • • • • • Negative single-stranded RNA Enveloped 150-200 nm in diameter Helical nucleocapsid Possess fusion protein which causes adjacent cells to fuse and form multinucleate giant cells (syncytia) Members of the genus Paramyxovirus possess neuraminidase They possess matrix (M) protein All possess hemagglutinin spikes with the exception of respiratory syncytial virus They have RNA reverse transcriptase Virus replicates in the cytoplasm 25 26 Replication • Replication is of a typical negativestranded RNA virus: • Virus enters a cell by fusion • RNA transcriptase synthesize (+) RNA which then enters into translation process • The virus is released by budding from the plasma membrane 27 Measles (Rubeola) • A highly infectious disease • Infection is acquired via droplets that enter the respiratory tract • Pathogenies • Incubation period: 10-14 days • Replication in lymph nodes, then viremia follows • Rash (due to reaction of cytotoxic T-cells with infected skin cells) first appears on the face and spreads to the trunk and limbs (maculopapular) • A maculopapular rash is a type of rash characterized by a flat, red area on the skin that is covered with small confluent bumps. • Koplik spots: • Koplik spots are small, red, irregularly-shaped spots with blue-white centers found on the mucosal surface of the oral cavity. • Complications may include secondary bacterial infection and encephalitis 28 maculopapular rash 29 Measles - Laboratory Diagnosis • Laboratory diagnosis is not needed since diagnosis is made on clinical grounds • Measles antigen can be detected in pharyngeal cells or urinary sediment with immunofluorescence • The measles genome can be identified by reverse transcriptase polymerase chain reaction (RT-PCR) in either of the aforementioned specimens • Characteristic cytopathologic effects, including multinucleated giant cells with cytoplasmic inclusion bodies, can be seen in Giemsa stained cells taken from the upper respiratory tract and urinary sediment • Antibody, especially immunoglobulin M (IgM), can be detected when the rash is present 30 Measles - Prophylaxis • Vaccination “live attenuated measles virus, a component of MMR” (measles, mumps and rubella) • Passive immunization using human immunoglobulin for immunocompromised children Multinucleated giant cells 31 Respiratory Syncytial Virus “RSV” • Respiratory syncytial virus is distributed worldwide and is recognized as the major pediatric respiratory tract pathogen. • It is the most common cause of viral pneumonia in children under age 5 years. • RSV is highly contagious. 32 RSV - Pathogenesis • Infects the respiratory tract, does not spread systemically • In newborns, the infection may be fatal because narrow airways are blocked by virusinduced pathology • Infants are not protected from infection by maternal antibody • Reinfection may occur after a natural infection 33 RSV - Laboratory Diagnosis • Isolation of the virus in continuous lines of human cells, e.g., HeLa, cytopathic effects with formation of syncytia appear after 2-10 days. • Immunofluorescence demonstrates viral antigen in cells from nasal washing. • Serological diagnosis is by demonstration of rising antibody titers in paired serum samples. 34 RSV - Prevention & Treatment • Prevention • Attempts to develop attenuated vaccines have so far met with little success; the use of recombinant DNA technology for making RSV vaccine is now being studied. • In the absence of a vaccine, limitation of spread within paediatric units, nurseries depends on good hygienic practice, such as hand washing, covering of the mouth when coughing or sneezing, and careful disposal of paper handkerchiefs. • Treatment • Small-scale trials of the nucleoside analogue ribavirin, given by continuous aerosol inhalation to babies with serious RSV infections, met with some success, but not enough to make it a routine treatment. • High titer human immunoglobulin or humanized monoclonal antibodies are efficacious in high-risk infants but the treatment is expensive and is used only in emergencies 35 Mumps • Mumps virus is the cause of acute, benign viral parotitis (painful swelling of the salivary glands). • Mumps is rarely seen in countries that promote use of the live vaccine, which is administered with the measles and rubella live vaccines. • The virus is most closely related to parainfluenza virus 2, but there is no cross-immunity with the parainfluenza viruses. 36 Mumps • The infection is acquired by the respiratory route. • Viremia is followed by generalized spread to various organs, including the parotid gland. • Complications • Orchitis • Meningitis • Control • Vaccination (component of MMR) • There is only one antigenic type of mumps virus, and it does not exhibit significant antigenic variation. Immunity is permanent after a single infection. • Laboratory studies are not usually required to establish the diagnosis of typical cases. • The diagnosis may be established by virus isolation and serological tests 37 Parainfluenza Viruses • Parainfluenza viruses, which were discovered in the late 1950s, are respiratory viruses that usually cause mild coldlike symptoms but can also cause serious respiratory tract disease. • Four serologic types within the parainfluenza genus are human pathogens. • Types 1, 2, and 3 are second only to RSV as important causes of severe lower respiratory tract infection in infants and young children. • They are especially associated with laryngotracheobronchitis (croup). • It involves the respiratory system and also includes the larynx or the vocal cords, the trachea, and bronchial tubes which forms the upper airways of the lungs. • Type 4 causes only mild upper respiratory tract infection in children and adults. 38 Parainfluenza Viruses • Unlike measles and mumps viruses, the parainfluenza viruses rarely cause viremia. • The viruses generally stay in the upper respiratory tract, causing only cold-like symptoms. • In approximately 25% of cases, the virus spreads to the lower respiratory tract, and in 2% to 3%, disease may take the severe form of laryngotracheobronchitis. 39 Parainfluenza Viruses • laboratory diagnosis • Immunofluorescence or ELISA to detect Ag • Virus Isolation • Serology: Serodiagnosis should be based on paired sera • Vaccination with killed vaccines is ineffective, possibly because they fail to induce local secretory antibody and appropriate cellular immunity. • No live attenuated vaccine is available. 40 Nipah and Hendra Viruses • A new paramyxovirus, Nipah virus, was isolated from patients after an outbreak of severe encephalitis in Malaysia and Singapore in 1998. • Nipah virus is more closely related to the Hendra virus, discovered in 1994 in Australia, than to other paramyxoviruses. • Both viruses have broad host ranges, including pigs, man, dogs, horses, cats, and other mammals. For Nipah virus, the reservoir is a fruit bat (flying fox). • The virus can be obtained from fruit contaminated by infected bats or amplified in pigs and then spread to humans. • The human is an accidental host for these viruses, but the outcome of human infection is severe. • Disease signs include flulike symptoms, seizures, and coma. • Of the 269 cases occurring in 1999, 108 were fatal. • Another epidemic in Bangladesh in 2004 had a higher mortality rate. 41